Lose up to 22%
Our most effective option for maximum weight loss results — with full lifestyle support included.
Lose up to 15%
A proven GLP-1 treatment with full lifestyle support included.
Everything you need to lose weight, all in one app.
Lose up to 22%
Our most effective option for maximum weight loss results — with full lifestyle support included.
Lose up to 15%
A proven GLP-1 treatment with full lifestyle support included.
Everything you need to lose weight, all in one app.
1️⃣ Mounjaro and Wegovy are both GLP-1-based treatments, but they differ in mechanisms, dosing protocols, and efficacy.
2️⃣ Mounjaro combines dual action (GIP and GLP-1), while Wegovy targets GLP-1 receptors only.
3️⃣ Proper dose selection depends on factors like BMI, comorbidities, and tolerance.
4️⃣ Gradual dose escalation helps mitigate common side effects like nausea.
5️⃣ Consulting with a weight loss specialist ensures safe and effective treatment planning.
When it comes to selecting the right dose of Mounjaro or Wegovy, understanding how each medication works is essential. Both Mounjaro and Wegovy are classified as GLP-1 receptor agonists, but Mounjaro also includes GIP agonism, offering a dual-hormone approach. This combination can enhance metabolic effects, potentially leading to more significant weight loss in some individuals.
For more insights on our treatments, visit our Treatments page.
One of the most critical aspects of using GLP-1 medications safely and effectively is the gradual dose escalation. Both Mounjaro and Wegovy require a titration period to reduce gastrointestinal side effects.
Starting Dose: 0.25 mg once weekly for the first four weeks.
Escalation: Gradually increase every four weeks (0.5 mg → 1 mg → 1.7 mg → 2.4 mg).
Maintenance: 2.4 mg per week. If intolerable, reduce to 1.7 mg.
Starting Dose: 2.5 mg once weekly for four weeks.
Escalation: Increase by 2.5 mg every four weeks, up to a maximum of 15 mg weekly.
Maintenance: Typically 10–15 mg, depending on individual tolerance.
Patient Profile: Consider factors like BMI, comorbid conditions (e.g., diabetes), and weight loss goals.
Tolerance Levels: Some patients may need to pause dose escalation if gastrointestinal symptoms become severe.
Metabolic Needs: Mounjaro may be more suitable for those with insulin resistance due to its dual action.
For more details on the pricing of these medications, visit our Medications and Pricing page.
Gradual dose escalation is key to minimizing side effects. Start slow and increase cautiously, as your healthcare provider advises.
Common side effects include nausea, vomiting, and diarrhea. Report any severe symptoms to your healthcare professional promptly.
Take your medication on the same day each week to maintain stable blood levels. Use a reminder or calendar to help with consistency.
Combining GLP-1 therapy with lifestyle changes—like a balanced diet and regular exercise—can enhance results. Learn more about starting your weight loss journey with us on our Thinking of Starting? page.
If you’re considering switching from one GLP-1 medication to another, consult your healthcare provider to ensure a smooth transition. Find out more about switching providers on our Switch Supplier page.
Choosing between Mounjaro and Wegovy—and determining the right dose—requires a personalized approach. By understanding each medication’s mechanisms and following a structured dosing protocol, you can optimize your weight loss outcomes while minimizing potential side effects. Always consult a healthcare provider for tailored guidance.
For any further questions, reach out to us via our Contact Us page.
No, combining these medications is not recommended due to overlapping mechanisms and increased risk of side effects.
Results vary, but noticeable weight loss typically occurs after 8–12 weeks when the target dose is reached.
Take the missed dose as soon as possible if within three days. Otherwise, skip it and continue with your next scheduled dose.
Yes, but it should be done under medical supervision to adjust dosing and manage potential side effects.
Wegovy is more commonly available on the NHS for specific BMI criteria. Mounjaro is primarily used for diabetes management but may expand for weight loss in the future.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7566932/
https://pubmed.ncbi.nlm.nih.gov/22041461/
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215256s005lbl.pdf
https://pmc.ncbi.nlm.nih.gov/articles/PMC10533252/
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
https://pmc.ncbi.nlm.nih.gov/articles/PMC7900946/
https://jme.bmj.com/content/early/2025/03/20/jme-2024-110374
https://researchbriefings.files.parliament.uk/documents/CBP-10171/CBP-10171.pdf
https://www.jmcp.org/doi/10.18553/jmcp.2024.23332
https://www.ncbi.nlm.nih.gov/books/NBK551568/
https://commonslibrary.parliament.uk/research-briefings/cbp-10171/
https://www.bmj.com/content/384/bmj-2023-076410
https://medlineplus.gov/druginfo/meds/a618008.html
